Home > Healthcare > Pharmaceuticals > Finished Drug Form > Urothelial Cancer Drugs Market

Urothelial Cancer Drugs Market – By Types (Urothelial, Squamous Cell, Adenocarcinoma), Treatment (Chemotherapy, Immunotherapy, Targeted Therapy), Gender, Route of Administration (Oral, Parenteral), End-use, Global Forecast 2024 ­ 2032

  • Report ID: GMI9754
  • Published Date: Jun 2024
  • Report Format: PDF

Urothelial Cancer Drugs Market Size

Urothelial Cancer Drugs Market size was valued at USD 3.2 billion in 2023 and is anticipated to grow at a CAGR of 12.1% between 2024 and 2032, driven by rising prevalence of urothelial cancer, particularly bladder cancer.

Urothelial Cancer Drugs Market

For instance, as per the report published by American Cancer Society, it has been estimated that in 2023, about 83,190 new cases of bladder cancer were diagnosed and about 16,840 deaths from bladder cancer were reported in U.S. Moreover, urothelial carcinoma (or UCC) accounts for about 90% of all bladder cancers. Thus, such rising prevalence of urothelial cancer globally increases the demand for novel drug therapeutics, thereby boosting the market growth.

Moreover, the rising innovations in cancer treatment, such as the development of targeted therapies and immunotherapies, have expanded the treatment options for urothelial cancer. These advancements have led to more effective and personalized treatment plans. Furthermore, significant investments by pharmaceutical companies in R&D to develop novel therapies are propelling market growth.

Urothelial carcinoma (also called transitional cell carcinoma) is cancer that begins in the urothelial cells, which line the urethra, bladder, ureters, renal pelvis, and some other organs. Urothelial carcinoma accounts for about 90% of all bladder cancers and 7% of all kidney cancers.

Urothelial Cancer Drugs Market Trends

  • Increasing prevalence of urothelial cancer significantly drives the growth of the market. For instance, as per an article published in January 2024, it has been reported that urothelial carcinoma is the 10th most common cancer globally with an almost 4 times higher prevalence in men. It is more prevalent in the elderly population with 80% of the cases getting diagnosed in people above 65 years of age.
  • Thus, the high prevalence of urothelial cancer necessitates an increasing demand for novel drug therapeutics, thereby driving market growth.
  • Moreover, the growing awareness and increase in cancer diagnostics rates for urothelial cancer contribute to an increased patient base seeking medical intervention, further boosting the market for these drugs.
  • Consequently, the rising prevalence of urothelial cancer not only increases the immediate demand for existing treatments but also stimulates ongoing innovation and market expansion in the long term.

Urothelial Cancer Drugs Market Analysis

Urothelial Cancer Drugs Market, By Types, 2021 – 2032 (USD Billion)

Based on the types, the global market is classified into urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. The urothelial carcinoma segment dominated the market with revenue of USD 1.7 billion in 2023.

  • The rising prevalence of urothelial carcinoma, particularly in developed regions, has significantly increased the demand for effective therapeutic options. Advances in diagnostic technologies have improved early detection rates, leading to more patients seeking treatment.
  • Additionally, the development and approval of targeted therapies and immunotherapies have revolutionized the treatment landscape, offering improved efficacy and better patient outcomes.
  • Further, growing awareness about the disease and the availability of advanced treatment options have also contributed to the high market share of the urothelial carcinoma segment.


Urothelial Cancer Drugs Market, By Treatment (2023)

Based on the treatment, the global urothelial cancer drugs market is classified into chemotherapy, immunotherapy, targeted therapy, and combination drug therapies. The immunotherapy segment dominated the market with market share of 41.5% in 2023.

  • The approval of several immunotherapy drugs by regulatory bodies like the FDA and the expansion of indications for these drugs to include urothelial cancer have increased their adoption in clinical practice.
  • Moreover, better efficacy and safety profile of immunotherapy drugs compared to traditional chemotherapy, make them a preferred choice for many patients and healthcare providers.
  • Thus, the increased awareness among healthcare professionals and patients about the benefits of immunotherapy for urothelial cancer, coupled with growing adoption of these treatments in clinical settings is fuelling market growth.

Based on gender, the urothelial cancer drugs market is classified into male and female. The male segment is expected to grow at 12.2% CAGR between 2024 - 2032.

  • Urothelial cancer, particularly bladder cancer, has a significantly higher incidence rate in men compared to women. This disparity drives a larger market for drugs targeting male patients.
  • Moreover, men are more likely to engage in lifestyle behaviors that increase the risk of urothelial cancer, such as smoking and occupational exposure to certain chemicals. These factors contribute to the higher incidence rates and consequently a higher demand for treatment options in males.
  • Furthermore, enhanced awareness campaigns and screening programs specifically targeting men have led to increased detection rates, further fostering the segmental growth.

Based on route of administration, the urothelial cancer drugs market is classified into oral and parenteral. The parenteral segment is expected to reach USD 7.5 billion by 2032.

  • Parenteral formulations, including intravenous (IV) and intramuscular (IM) injections, allow for rapid delivery of the drug into the bloodstream, leading to a quicker therapeutic effect. This is particularly critical in oncology, where timely intervention can significantly impact patient outcomes.
  • Moreover, many urothelial cancer patients have difficulty swallowing pills due to their medical condition or treatment side effects (e.g., nausea, vomiting). Parenteral administration bypasses the gastrointestinal tract, making it a preferred route for these patients.
  • Furthermore, technological advancement in drug delivery technologies, such as nanoparticle-based carriers and liposomal formulations, have improved the stability and efficacy of parenteral drugs. These advancements contribute to the growing preference for parenteral routes in cancer therapy.

Based on end-use, the urothelial cancer drugs market is classified into hospitals, cancer treatment centers, ambulatory surgical centers, and other end-users. The hospitals segment is expected to exhibit 12.4% CAGR between 2024 - 2032.

  • Hospitals hold a significant market share in the urothelial drugs market due to their critical role in diagnosing and treating urothelial cancers, including bladder cancer.
  • The advanced infrastructure, availability of specialized healthcare professionals, and access to cutting-edge diagnostic tools and therapeutic options in hospitals contribute to their dominance in this market.
  • Additionally, hospitals are often the primary settings for administering complex treatments such as chemotherapy, immunotherapy, and targeted therapies, which are essential for managing urothelial cancers.
  • Further, the presence of multidisciplinary teams in hospitals ensures comprehensive care, from initial diagnosis through to treatment and follow-up, thereby driving the demand for urothelial drugs within these institutions. 


North America Urothelial Cancer Drugs Market, 2021 – 2032 (USD Billion)

In 2023, North America secured a substantial market share of 40.5% in the global urothelial cancer drugs market and is expected to dominate throughout the forecast period.

  • North America sees substantial investments in research and development from both public and private sectors. This fosters the discovery and development of new drugs and therapies for urothelial cancer.
  • Moreover, the existence of favorable reimbursement policies and health insurance coverage in countries like the U.S. and Canada facilitates patient access to expensive urothelial cancer treatments, thus supporting market growth.
  • Furthermore, high levels of awareness about cancer and robust screening programs help in early diagnosis and treatment of urothelial cancer, thereby increasing the need for effective drugs.  

The urothelial cancer drugs market in U.S. is expected to exhibit 12% CAGR between 2024 - 2032.

  • The increasing prevalence of urothelial cancer in the U.S. significantly drives the demand for effective treatments. Factors such as an aging population and lifestyle risks (e.g., smoking) contribute to the higher incidence of this type of cancer.
  • In addition, the regulatory framework in the U.S., particularly through the Food and Drug Administration (FDA), plays a crucial role. Expedited approval processes for breakthrough therapies and orphan drugs can accelerate the availability of new urothelial cancer treatments, further enhancing the market growth.

Germany urothelial cancer drugs market is anticipated to witness lucrative growth over the forecast years.

  • Germany has a notable prevalence of risk factors associated with urothelial cancer, such as smoking, occupational exposure to carcinogens (common in industries like dye, rubber, and chemical manufacturing), and chronic bladder conditions. These factors contribute to a higher incidence rate, increasing the need for treatment options.
  • Moreover, the regulatory environment in Germany is conducive to the approval and introduction of new drugs. The Federal Institute for Drugs and Medical Devices (BfArM) ensures a streamlined approval process while maintaining high standards of safety and efficacy, facilitating quicker market access for new urothelial cancer treatments.

India urothelial cancer drugs market is expected to grow with a significant CAGR during the forecast period.

  • Rapid urbanization and changes in lifestyle, including increased smoking rates and exposure to environmental toxins, have contributed to the rise in urothelial cancer cases, driving the need for effective treatments.
  • Moreover, the expansion of health insurance coverage in India has made cancer treatments more accessible and affordable for a larger segment of the population. This has resulted in higher utilization of urothelial cancer drugs in the country.

Brazil secured a substantial market share in the global urothelial cancer drugs market.

  • Brazil's efforts to improve its healthcare infrastructure, including expanding access to cancer screening, diagnosis, and treatment facilities, can lead to earlier detection and treatment of urothelial cancer, thereby driving the demand for related drugs.

Urothelial Cancer Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture advanced urothelial cancer drugs products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The market players are actively adopting a multi-pronged approaches to address the rising demand for urothelial cancer drugs.

Urothelial Cancer Drugs Market Companies

Prominent players operating in the urothelial cancer drugs industry are as mentioned below:

  • AstraZeneca Plc
  • Bristol Myers Squibb
  • Eisai Co. Ltd.
  • Exelixis, Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Science, Inc.
  • Johnson & Johnson (Janssen Biotech)
  • Merck & Co. Inc
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • UroGen Pharma, Inc

Urothelial Cancer Drugs Industry News:

  • In March 2024, the U.S. Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). The approval of this combination therapy is an important treatment advancement for patient’s suffering from urothelial cancer. Combining nivolumab and cisplatin led to significantly improved survival rates among patients with advanced urothelial cancer compared with standard chemotherapy. This helped the company to increase sales of its product.
  • In December 2023, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial cancer. This helped the company to increase applications of its product, thereby increasing its sales.

The urothelial cancer drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Types

  • Urothelial carcinoma
  • Squamous cell carcinoma
  • Adenocarcinoma

Market, By Treatment

  • Chemotherapy
  • Immunotherapy
  • Targeted therapy
  • Combination drug therapies

Market, By Gender

  • Male
  • Female

Market, By Route of Administration

  • Oral
  • Parenteral

Market, By End-use

  • Hospitals
  • Cancer treatment centers
  • Ambulatory surgical centers
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudia Arabia
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global urothelial cancer drugs market was valued at USD 3.2 billion in 2023 and is anticipated to grow at 12.1% CAGR during 2024-2032, driven by rising prevalence of urothelial cancer, particularly bladder cancer.

The urothelial carcinoma segment of the market recorded a revenue of USD 1.7 billion in 2023, owing to its high prevalence.

North America urothelial cancer drugs market secured 40.5% revenue share in 2023 and is expected to dominate through 2032, owing to high levels of awareness about cancer and robust screening programs.

Gilead Science, Inc, Johnson & Johnson (Janssen Biotech), Merck & Co. Inc, Merck KGaA, Novartis AG, Pfizer, Inc, and UroGen Pharma, Inc among others.

Urothelial Cancer Drugs Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 326
  • Countries covered: 22
  • Pages: 186
 Download Free Sample